The effect of human umbilical cord matrix stem cell transplantation therapy on pregnancy rate of patient with premature ovarian failure and endometrial repair disorders

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900021618

Enrollment

Unknown

Registered

2019-03-01

Start date

2019-05-01

Completion date

Unknown

Last updated

2019-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

premature ovarian failure and endometrial repair disorders

Interventions

1:Conventional hormone replacement therapy combined with hysteroscopic curettage

2:Conventional hormone replacement therapy combined with hysteroscopic curettage + huc-mscs ovarian transplantation

3:Conventional hormone replacement therapy combined with hysteroscopic curettage + huc-mscs intrauterine transplantation

4:Conventional hormone replacement therapy combined with hysteroscopic curettage + huc-mscs ovary and uterine transplantation

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. female aged 20-40 years with fertility requirement, diagnosed as premature ovarian failure (premature ovarian failure group) and severe intrauterine adhesion and thin uterus (endometrium repair); 2. for premature ovarian failure group: serum FSH > 40 IU/L was detected twice everay 4-6 weeks, and amenorrhea occurred for 4 month. For endometriial repair group: who were diagnosed with severe intrauterine adhesion of who still had intrauterine adhesion after two or more intrauterine surgeries, and thickness less than 7 mm; 3. sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. abnormal karyotype or RIF family history; 2. autoimmune disease, or ovarian or adrenal autoantibody screening positive; 3. polycystic ovary syndrome; 4. high GnRH sensitivity; 5. severe endometriosis; 6. breast cancer and ovarian cancer; 7. other malignant tumors, hepatitis and other diseases; 8. HIV +; 9. BMI >30; 10. have a history of surgery or other related diseases.

Design outcomes

Primary

Measure	Time frame
Clinical pregnancy rate;No complication delivery rate;	—

Secondary

Measure	Time frame
endometrial thickness;morphology of the uterine cavity;Uterine arterial blood flow;Uterine receptivity markers;Pulse index and resistance index of uterine artery;Serum hormone concentration: FSH, LH, E2, P4 and AMH;Menstrual status;ovarian volume;Number of follicles;Dominant follicle count;Ovarian blood flow;The responsiveness of ovaries to gonadotropins;The number of oocytes that are available;In vitro fertilization rate and high quality embryo rate;Success rate of planting;No complication delivery rate;The proportion of immune cells in the blood: CD3-/CD56+ NK cell, Th1/Th2, CD3+IL-17+ T cell, CD4+IL-17+ T cell, CD8+IL-17+ T cell, CD4+ Foxp3+ T, CD8+ Foxp3+ T cell;Serum levels of inflammatory cytokines;Serum antibody level;Ovarian growth factor;	—

Measure

Time frame

endometrial thickness;morphology of the uterine cavity;Uterine arterial blood flow;Uterine receptivity markers;Pulse index and resistance index of uterine artery;Serum hormone concentration: FSH, LH, E2, P4 and AMH;Menstrual status;ovarian volume;Number of follicles;Dominant follicle count;Ovarian blood flow;The responsiveness of ovaries to gonadotropins;The number of oocytes that are available;In vitro fertilization rate and high quality embryo rate;Success rate of planting;No complication delivery rate;The proportion of immune cells in the blood: CD3-/CD56+ NK cell, Th1/Th2, CD3+IL-17+ T cell, CD4+IL-17+ T cell, CD8+IL-17+ T cell, CD4+ Foxp3+ T, CD8+ Foxp3+ T cell;Serum levels of inflammatory cytokines;Serum antibody level;Ovarian growth factor;

—

Countries

China

Contacts

Public ContactShaorong Gao

First Maternity and Infant Hospital Affiliated to Tongji University

gaoshaorong@tongji.edu.cn+86 021-65985182

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026